Display options
Cite
Kimmel AD, Resch SC, Anglaret X, et al. Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. Cost Eff Resour Alloc. 2012;10(1):12doi: 10.1186/1478-7547-10-12.
Kimmel, A. D., Resch, S. C., Anglaret, X., Daniels, N., Goldie, S. J., Danel, C., Wong, A. Y., Freedberg, K. A., & Weinstein, M. C. (2012). Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. Cost effectiveness and resource allocation : C/E, 10(1), 12. https://doi.org/10.1186/1478-7547-10-12
Kimmel, April D, et al. "Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability." Cost effectiveness and resource allocation : C/E vol. 10,1 (2012): 12. doi: https://doi.org/10.1186/1478-7547-10-12
Kimmel AD, Resch SC, Anglaret X, Daniels N, Goldie SJ, Danel C, Wong AY, Freedberg KA, Weinstein MC. Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. Cost Eff Resour Alloc. 2012 Sep 19;10(1):12. doi: 10.1186/1478-7547-10-12. PMID: 22992315; PMCID: PMC3502124.
Copy Download .nbib Format: NLM
Share it on

Cost Eff Resour Alloc. 2012 Sep 19;10(1):12. doi: 10.1186/1478-7547-10-12.

Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability.

Cost effectiveness and resource allocation : C/E

April D Kimmel, Stephen C Resch, Xavier Anglaret, Norman Daniels, Sue J Goldie, Christine Danel, Angela Y Wong, Kenneth A Freedberg, Milton C Weinstein

Affiliations

  1. Department of Healthcare Policy and Research, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA. [email protected].

PMID: 22992315 PMCID: PMC3502124 DOI: 10.1186/1478-7547-10-12

Abstract

BACKGROUND: In resource-limited settings, HIV budgets are flattening or decreasing. A policy of discontinuing antiretroviral therapy (ART) after HIV treatment failure was modeled to highlight trade-offs among competing policy goals of optimizing individual and population health outcomes.

METHODS: In settings with two available ART regimens, we assessed two strategies: (1) continue ART after second-line failure (Status Quo) and (2) discontinue ART after second-line failure (Alternative). A computer model simulated outcomes for a single cohort of newly detected, HIV-infected individuals. Projections were fed into a population-level model allowing multiple cohorts to compete for ART with constraints on treatment capacity. In the Alternative strategy, discontinuation of second-line ART occurred upon detection of antiretroviral failure, specified by WHO guidelines. Those discontinuing failed ART experienced an increased risk of AIDS-related mortality compared to those continuing ART.

RESULTS: At the population level, the Alternative strategy increased the mean number initiating ART annually by 1,100 individuals (+18.7%) to 6,980 compared to the Status Quo. More individuals initiating ART under the Alternative strategy increased total life-years by 15,000 (+2.8%) to 555,000, compared to the Status Quo. Although more individuals received treatment under the Alternative strategy, life expectancy for those treated decreased by 0.7 years (-8.0%) to 8.1 years compared to the Status Quo. In a cohort of treated patients only, 600 more individuals (+27.1%) died by 5 years under the Alternative strategy compared to the Status Quo. Results were sensitive to the timing of detection of ART failure, number of ART regimens, and treatment capacity. Although we believe the results robust in the short-term, this analysis reflects settings where HIV case detection occurs late in the disease course and treatment capacity and the incidence of newly detected patients are stable.

CONCLUSIONS: In settings with inadequate HIV treatment availability, trade-offs emerge between maximizing outcomes for individual patients already on treatment and ensuring access to treatment for all people who may benefit. While individuals may derive some benefit from ART even after virologic failure, the aggregate public health benefit is maximized by providing effective therapy to the greatest number of people. These trade-offs should be explicit and transparent in antiretroviral policy decisions.

References

  1. Health Econ Policy Law. 2006 Jan;1(Pt 1):79-90 - PubMed
  2. PLoS Med. 2009 Oct;6(10):e1000173 - PubMed
  3. Ann Intern Med. 1997 Jun 15;126(12):946-54 - PubMed
  4. Implement Sci. 2010 May 26;5:39 - PubMed
  5. J Health Serv Res Policy. 2001 Jul;6(3):163-9 - PubMed
  6. J Acquir Immune Defic Syndr. 2010 Jul;54(3):258-68 - PubMed
  7. Ann Intern Med. 2000 Sep 19;133(6):401-10 - PubMed
  8. N Engl J Med. 2006 Nov 30;355(22):2283-96 - PubMed
  9. Health Aff (Millwood). 1997 Sep-Oct;16(5):83-92 - PubMed
  10. J Acquir Immune Defic Syndr. 2011 Jul 1;57 Suppl 1:S34-9 - PubMed
  11. N Engl J Med. 2011 Aug 11;365(6):493-505 - PubMed
  12. Trop Med Int Health. 2008 Jul;13(7):870-9 - PubMed
  13. Lancet. 1999 May 1;353(9163):1463-8 - PubMed
  14. Antivir Ther. 2007;12(4):543-51 - PubMed
  15. Antivir Ther. 2003 Oct;8(5):385-93 - PubMed
  16. Health Aff (Millwood). 2000 Sep-Oct;19(5):100-11 - PubMed
  17. Sex Transm Infect. 2008 Aug;84 Suppl 1:i24-i30 - PubMed
  18. BMJ. 2011 Nov 29;343:d7755 - PubMed
  19. Health Policy. 2010 Oct;97(2-3):187-94 - PubMed
  20. Lancet. 2010 Jun 12;375(9731):2092-8 - PubMed
  21. AIDS. 2007 May 11;21(8):973-82 - PubMed
  22. Bull World Health Organ. 2008 Sep;86(9):678-87 - PubMed
  23. Health Policy. 1999 Oct;49(1-2):13-26 - PubMed
  24. AIDS. 2012 May 15;26(8):929-38 - PubMed
  25. Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15 - PubMed
  26. Int J STD AIDS. 2008 May;19(5):291-6 - PubMed
  27. Lancet. 2004 Jul 3-9;364(9428):29-34 - PubMed
  28. AIDS. 2002 Jul 5;16(10):1363-70 - PubMed
  29. Clin Infect Dis. 2009 Aug 1;49(3):454-62 - PubMed
  30. BMJ. 2010 Jul 20;341:c3900 - PubMed
  31. AIDS. 2008 Apr 23;22(7):873-82 - PubMed
  32. Trop Med Int Health. 2008 Jul;13(7):904-13 - PubMed
  33. AIDS Res Hum Retroviruses. 2007 Nov;23(11):1338-47 - PubMed
  34. Trop Med Int Health. 2007 Nov;12(11):1315-22 - PubMed
  35. N Engl J Med. 2006 Sep 14;355(11):1141-53 - PubMed
  36. Bull World Health Organ. 2007 Feb;85(2):116-23 - PubMed

Publication Types

Grant support